$47 is the price but will probably goto $48.5 until ex div date. Then will drift back to $47 until suvorexant is approved then go up to $49 (maybe) depending on timing. What we all can agree on is 2nd qtr numbers will be not good so buyback will need to kickin to prop it up. RULE - Anytime it hist $50 buy PUTS as there is no support for $50
MRK is a dog. Bad pipeline. Bad management. Falling revenues. The reputation can only carry you for so long, then the mutual funds start to sell. Once the institutional investors start to pare shares, it's in big trouble. Shorting this one big.
Sentiment: Strong Sell
Agreed I still think its odd that Dr. Peter Kim left. I think he had issue with MRK moving research to Asia and maybe wanting to cut some corners to speed things up? We all know next qtr numbers will be a miss. Then I see nothing to hodl this price $46 maybe even as low as $44 by end of 2013
I just don't know how MRK is still justifying its stock price. The largest drug Singulair is gone, Januvia is growing, Consumer Care is growing and there are some good things in the pipeline that are going to take years to come out (including cancer drugs). We all know Q2 is probably not going to be well. One would think this stock would be going down.